Linkedin
en
fr

Pipeline

From preclinical validation to clinical readiness

R&D Pipeline

Innovative therapeutic programs & enabling platforms

Program Modality Indication Discovery Preclinical IND-Enabling Phase I/II
Itero-101 + NK
Cells
Small molecule
+ NK cell
therapy
 Pancreatic
Cancer
Active 		— —
NK Expansion
Platform
Cell therapy
platform
 Platform
Active 		— — —
Itero-101 +
Other Agents
Combination
strategies
 Other Cancer
Types		 Planned — — —

Development stage definitions

Discovery Target ID, hit-to-lead  ·  Preclinical In vitro / in vivo efficacy and safety  ·  IND-Enabling Toxicology, CMC, regulatory filing  ·  Phase I/II Clinical safety & preliminary efficacy
✓ Milestone achieved · → Active / in progress · Planned Research initiated · — Not yet initiated

Itero-101 + NK Cells

Pancreatic Cancer

Small molecule + NK cell therapy

Discovery Preclinical IND Phase I/II

NK Expansion Platform

Platform

Cell therapy platform

Discovery Preclinical IND Phase I/II

Itero-101 + Other Agents

Other tumors

Combination strategies

Planned Preclinical IND Phase I/II

Development stage definitions

Discovery — Target ID, hit-to-lead
Preclinical — In vitro / in vivo efficacy and safety
IND-Enabling — Toxicology, CMC, regulatory filing
Phase I/II — Clinical safety & preliminary efficacy

✓ Achieved Active Planned Not initiated
Our PIPELINE

Development Roadmap

Building on our preclinical proof of concept and intellectual property foundation, IterOnco's development plan follows a milestone-driven approach.
IterOnco's development strategy leverages the repositioning advantage of Itero-101 to accelerate timelines and de-risk each phase before advancing to the next.
Partner with Us
Our PIPELINE

Development Roadmap

Building on our preclinical proof of concept and intellectual property foundation, IterOnco's development plan follows a milestone-driven approach.
IterOnco's development strategy leverages the repositioning advantage of Itero-101 to accelerate timelines and de-risk each phase before advancing to the next.
Partner with Us
Our PIPELINE

Development Roadmap

Building on our preclinical proof of concept and intellectual property foundation, IterOnco's development plan follows a milestone-driven approach.
IterOnco's development strategy leverages the repositioning advantage of Itero-101 to accelerate timelines and de-risk each phase before advancing to the next.
Partner with Us

Development Roadmap

Building on our preclinical proof of concept and intellectual property foundation, IterOnco's development plan follows a milestone-driven approach.
IterOnco's development strategy leverages the repositioning advantage of Itero-101 to accelerate timelines and de-risk each phase before advancing to the next.
Partner with Us
2029+

Phase I/II clinical trial initiation in pancreatic cancer

2028–2029

IND/CTA preparation

2026–2028

Preclinical development and GLP/GMP regulatory preparation

2025–2027

Mechanistic and in vitro pharmacological studies